Following our oral presentation at the ASGCT 2026 Annual Meeting in Boston, NewBiologix is proud to be featured in a newly published Molecular Therapy meeting report covering the latest developments in AAV cell line development and engineering.
The report summarizes a session held on May 13, 2026, that brought together researchers addressing one of the field's central manufacturing challenges: while triple-transfection remains the fastest route to rAAV for clinical work, it comes with high plasmid costs, batch-to-batch inconsistency, and plasmid-derived impurities. Stable producer cell lines offer a path around these limitations, but getting there requires solving a hard problem, since several of the viral genes needed for production are toxic to cells when expressed constitutively. The session highlighted progress from multiple groups working to solve exactly that.
As part of the session, Efrain Guzman, PhD MBA, VP of Innovation & Business Development at NewBiologix, shared an overview of NewBiologix's platform: a regulated, genomically integrated HEK293 producer cell line built to replace transient transfection altogether. Rather than relying on GMP-grade plasmids, our system integrates the AAV Rep and Cap genes, adenoviral helper functions, and the gene of interest directly into the genome, an approach the report notes "reduces batch-to-batch variability, simplifies the supply chain, and enables more scalable production" in suspension bioreactors.
The platform is built on our Xcell Eng-HEK293 host, a clonally derived and thoroughly characterized cell line that showed improved genomic stability over its parental line. At its core is our proprietary Regulated Network System (RNS), a set of feedback-controlled activator and repressor circuits that keep cytotoxic genes like Rep and the adenoviral helpers tightly off until induction, then drive strong, sustained expression once triggered. Producer lines are built up in stages, ultimately yielding single cells capable of running the entire rAAV production process internally. Early optimization work has already pushed pool-level titers up by more than two orders of magnitude under transient conditions, pointing toward a clear path to even higher performance through clonal selection.
We're proud to see this work recognized in Molecular Therapy and grateful to the ASGCT community for the opportunity to share it.
Read the full meeting report in Molecular Therapy (membership required): https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(26)00593-9
